Annual Meeting & Pre-Conference Programs • Schedule

The following was the schedule for the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC) taking place Nov. 7–11, 2018, in Washington, D.C.

Browse the full schedule by day by clicking the blue tabs below. Also, visit the dedicate landing pages for the Pre-Conference Programs  and 33rd Annual Meeting page to learn more.

Click here to download the full schedule

Session I: Therapeutic Strategies to Overcome Immune Resistance

2 p.m.

Introduction
Daniel S. Chen, MD, PhD – IGM Biosciences

2:05 p.m.

Mechanisms of Immune Escape to Checkpoint Inhibitors
Priti S. Hegde, PhD – Genentech, Inc.

2:25 p.m.

A Novel Inflammasome-Wnt Ligand Signaling Axis Promotes Immune Escape During Anti-PD-1 Antibody Immunotherapy
Brent A. Hanks, MD, PhD – Duke University Medical Center

2:40 p.m.

Cell Proliferation Defines an Additional Mechanism of Immune Escape in Non-small Cell Lung Cancer
Grace Dy, MD – Roswell Park Comprehensive Cancer Center

2:55 p.m.

Melanoma Tissue Microarray Characterization with Digital Spatial Profiling Identifies Biomarkers of Clinical Response to Immunotherapy
David Rimm, MD, PhD – Yale University

3:10 p.m.

Primary and Secondary Mechanisms of Resistance to Autologous Anti-CD19 CAR T cell Therapy in Refractory Non-Hodgkin's Lymphoma (rNHL)
John Rossi, MD – Kite Pharma

3:25 p.m.

Group Discussion

3:45 p.m.

Break

4 p.m.

Panel Discussion: Can CAR T cells Overcome and Influence Resistance to Other Treatment Modalities & New Concepts in Immune Checkpoint Blockade Designed to Overcome Local Immune Resistance
Co-Moderators:
Adrian Bot, MD, PhD – Kite a Gilead Company
Eric H. Rubin, MD – Merck
Panelists:
Daniel S. Chen, MD, PhD – IGM Biosciences
Gordon J. Freeman, PhD – Dana-Farber Cancer Center
Carl H. June, MD – University of Pennsylvania
Alan Korman, PhD – Bristol-Myers Squibb
Marcela Maus, MD, PhD – Massachusetts General Hospital

Wednesday, Nov. 7

Immune Escape: Current Understanding of Mechanisms and Advances in Therapeutics Approaches

Session II: Underlying Mechanisms of Immune Escape

5 p.m.

Analysis of TIL from Human Carcinoma Combined with Tissue Imaging and in vitro Models Uncovers Tumor-inflicted T Cell Deviations Related to Immune Escape and Strategies of Intervention
Elfriede Noessner, PhD – Helmholtz Zentrum Munchen

5:15 p.m.

Impact of Tumor Inherent Interferons on Immune Reactivity and Personalized Therapy in Triple Negative Breast Cancer
Natasha K. Brockwell, BBiomed (Hons) – La Trobe Institute for Molecular Science

5:30 p.m.

Repurposing Anti-Pathogen Vaccines to Overcome Immune Escape within the Tumor Microenvironment
Andrew Zloza, MD, PhD – Rutgers Cancer Institute of New Jersey

5:45 p.m.

First in Human Data in Advanced Solid Tumors of NANT Cancer Vaccine: A Novel Temporospatial Orchestration of the Innate (NK) & Adaptive Immune System to Induce Antigen Cascade & Immunogenic Cell Death
Patrick Soon-Shiong – NANT Cancer Immunotherapy, Inc.

6 p.m.

Group Discussion

6:20 p.m.

Break

6:35 p.m.

Panel Discussion: Immune Resistance and the Tumor Micronenvironment & Using Oncolytic Immunotherapy to Overcome Immune Resistance in the Tumor Microenvironment
Co-Moderators:
Alessandra Cesano, MD, PhD – NanoString Inc.
Howard L. Kaufman, MD, FACS – Replimune Group Inc.
Panelists: Robert Coffin, PhD – Replimune Group Inc.
George Coukos, MD, PhD – University of Lausanne
Francesco M. Marincola, MD – Refuge Biotechnologies
Ira Mellman, PhD – Genentech/Roche
Ryan Sullivan, MD – Massachusetts General Hospital
Dmitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

7:35 p.m.

Underlying Mechanisms of Immune Escape
Thomas F. Gajewski, MD, PhD – University of Chicago

Closing

7:55 p.m.

Salil Patel, PhD – Bristol-Myers Squibb

Immune Escape Reception

8 p.m.

Reception

Thursday, Nov. 8

Workshop on Nutrition, Metabolism and the Microbiome in Cancer Therapy

Introduction

8 a.m.

Laurence Zitvogel, MD, PhD – Institute Gustave Roussy

Session I: The Impact of the Microbiome on Cancer Therapy

8:05 a.m. The Evolving Role of the Microbiome on Response to Cancer Therapy
Laurence Zitvogel, MD, PhD – Institute Gustave Roussy

8:30 a.m. Mechanistic Insights Into the Influence of Gut Microbiota on Anti-Tumor Immunity
Thomas F. Gajewski, MD, PhD – University of Chicago

9:00 a.m. The Microbiome as a Biomarker and a Therapeutic Target
Jennifer A. Wargo, MD, MMSc – University of Texas MD Anderson Cancer Center

9:30 a.m. Panel Discussion
Moderator: 
Laurence Zitvogel, MD, PhD – Institute Gustave Roussy
Panelists: Jennifer A. Wargo, MD, MMSc – University of Texas MD Anderson Cancer Center
Thomas F. Gajewski, MD, PhD – University of Chicago

9:45 a.m.

Break

Session II: Interplay of Nutrition, Metabolism, and the Microbiome

10:00 a.m. The Influence of Nutrition on the Microbiome and Immune Function
Guido Kroemer, MD, PhD – Institute Gustave Roussy

10:30 a.m.

Harnessing Diet and the Microbiome for Cancer Patients and Survivors
Carrie Daniel-MacDougall, MPH, PhD – University of Texas MD Anderson Cancer Center

11:00 a.m.

Homeostatic and Inflammatory Immune Responses to Human Microbiotas in Gnotobiotic Mice
Graham Britton, PhD – Icahn School of Medicine at Mount Sinai


11:30 a.m.

The Interplay Between Diet, Intestinal Microbiota and Colorectal Cancer
Christian Jobin, PhD – University of Florida

Panel Discussion

Noon Moderator: Laurence Zitvogel, MD, PhD – Institute Gustave Roussy
Panelists:
Thomas F. Gajewski, MD, PhD – University of Chicago
Jennifer Wargo, MD, MMSc – University of Texas MD Anderson Cancer Center
Guido Kroemer, MD, PhD – Institute Gustave Roussy
Carrie Daniel-MacDougall, PhD – University of Texas MD Anderson Cancer Center
Christian Jobin, PhD – University of Florida
Graham Britton, PhD – Icahn School of Medicine at Mount Sinai

Primer on Tumor Immunology and Cancer Immunotherapy™

Introduction

8 a.m.

Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

Session I: Generating Anti-Tumor Immunity

8:05 a.m. Adaptive Immunity to Tumors: Laying the Foundation for Immunotherapy

Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine


8:35 a.m. Dendritic Cells
Tyler Curiel, MD – UT Health San Antonio

9:05 a.m. Harnessing Natural Killer Cells to Potentiate Antitumor Immunity
Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai

9:35 a.m. Panel Discussion

9:55 a.m.

Break

Session II: Breaking Through the Barriers - Passive Immunotherapy

10:10 a.m. Introduction
Timothy NJ Bullock, PhD – University of Virginia

10:15 a.m.

Cancer Vaccines : From Ex Vivo Production to In Vivo Vaccination
Tanja de Gruijl, PhD – VU University Medical Center


10:45 a.m. Monoclonal Antibodies and Their Derivatives
Charles G. Drake, MD, PhD – Columbia University

11:15 a.m. Cytokines in Cancer: Biology and Therapy
Kim A. Margolin, MD – City of Hope

11:45 a.m. Panel Discussion

Session III: Analysis of Resistance and Response

1:05 p.m. Introduction
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

1:10 p.m. Mechanisms of Extrinsic Resistance : A Miserable Microenvironment
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center

1:40 p.m. Mechanisms of Resistance: Checkpoint Receptors
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

2:10 p.m. A High-dimensional Assay and Analysis Platform to Discover Immune Correlates of Cancer Immunotherapy
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai

2:40 p.m. Panel Discussion

3:10 p.m.

Break

Session IV: Current IO Immunotherapy

3:25 p.m. Introduction
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

3:30 p.m. Adoptive T Cell Therapy
Patrick Hwu, MD – University of Texas MD Anderson Cancer Center

4 p.m. Combination Therapies
Leisha Emens, MD, PhD – University of Pittsburgh

4:30 p.m. Panel Discussion

4:50 p.m. Closing
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

Thursday, Nov. 8

Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials Workshop

Introduction

2 p.m.

Marc Theoret, MD – U.S. Food & Drug Administration, OHOP
Howard Kaufman, MD, FACS – Replimune Group, Inc.

Session I

Pseudoprogression with Immuno-oncology Therapeutics - Current Challenges with Evaluation

2:10 p.m. Pseudoprogression and Current Clinical Challenges in the Management of Patients on Immuno-Oncology Therapy 
Kim Margolin, MD – City of Hope

2:30 p.m. Immune-Modified Response Criteria in Clinical Development Programs of Immuno-Oncology Therapeutics
Sanjay Goel, MD – Montefiore Medical Center

2:50 p.m. Regulatory Perspectives with Use of Immune-modified Response Criteria for Assessment of Surrogate Clinical Efficacy Endpoints for Registration Trials
Patricia Keegan, MD – U.S. Food and Drug Administration

3:10 p.m. Panel Discussion

Moderator: Marc Theoret, MD – U.S. Food & Drug Administration, OHOP 
Panelists: Peter Bross, MD – U.S. Food & Drug Administration, CBER, DCEPT
David Feltquate, MD, PhD – Bristol Myers Squibb
Sanjay Goel, MD – Montefiore Medical Center
Patricia Keegan, MD – U.S. Food and Drug Administration
Kim Margolin, MD – City of Hope
Steven Silverstein, MBA – Melanoma Research Foundation
Jon Wigginton, MD – MacroGenics, Inc.

3:55 p.m.

Break

Session II

Evaluating Surrogate Endpoints for IO Drug Development: “New and renewed” Concepts and Perspectives

4:10 p.m. Clinical Trial Endpoints Considerations for Evaluating Efficacy in Immuno-Oncology Clinical Trials
David McDermott, MD – Beth Israel Deaconess Medical Center

4:30 p.m. Beyond Conventional Tumor-Based Measurements: Analysis Considerations for Clinical Efficacy Endpoints to More Fully Capture the Benefit of IO Therapeutics
Rajeshwari Sridhara, PhD – U.S. Food & Drug Administration

4:50 p.m. How to Integrate Biomarkers and Other Correlates of Response Into the Regulatory Landscape

Genevieve Boland, MD, PhD – Massachusetts General Hospital

5:10 p.m. Panel Discussion

Moderator: Howard Kaufman, MD, FACS – Replimune Group Inc.
Panelists: Genevieve Boland, MD, PhD – Massachusetts General Hospital
Samir Khleif, MD – Georgetown University
Ke Liu, MD, PhD – U.S. Food and Drug Administration, CBER
David McDermott, MD – Beth Israel Deaconess Medical Center
Reena Philip, PhD – U.S. Food & Drug Administration
Meredith Regan, ScD – Dana-Farber Cancer Institute
Lawrence H. Schwartz, MD – Columbia University College of Physicians and Surgeons
Rajeshwari Sridhara, PhD – U.S. Food & Drug Administration

5:55 p.m. Closing

Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
Ke Liu, MD, PhD – Food and Drug Administration, CBER

Grant Writing: From Start to Finish, and Then Starting Again

Introduction

6:30 p.m. Jennifer Guerriero, PhD – Dana-Farber Cancer Institute

Session Schedule

6:35 p.m. Obtaining Funding in Academia - Identifying and Selecting the Appropriate Grant 
Pawel Kalinski, MD, PhD – Roswell Park

6:55 p.m. Obtaining Funding in Academia - Mechanics of Grant Writing
Thomas Gajewski, MD, PhD – University of Chicago

7:15 p.m. NIH/NCI Grants: The NIH Grant Review Process
Denise  R. Shaw, PhD – National Institutes of Health

7:35 p.m.

Melanoma Research Alliance (MRA)/Foundation Funding
Kristen Mueller, PhD – Melanoma Research Alliance


7:55 p.m. Panel Discussion
Moderator:
Lorenzo Falchi, MD – Columbia University Medical Center

8:25 p.m. Closing
Ana Carrizosa Anderson, PhD – Harvard Medical School

Friday, Nov. 9

Annual Meeting

7:15 a.m.

Presidential Champagne Toast & Membership Business Meeting

Presidential Welcome

8 a.m.

Lisa Butterfield, PhD – University of Pittsburgh

Session 100: FDA & SU2C Update Session

8:05 a.m.

Food & Drug Administration Update: Cell and Gene Therapy
Raj Puri, MD, PhD – Food & Drug Administration

8:20 a.m.

Stand Up To Cancer Update
Carl H. June – University of Pennsylvania

Session 101: Keynote Address

8:35 a.m.

Introduction
Lisa H. Butterfield – University of Pittsburgh

8:40 a.m.

Next Gen T Cell-based Immunotherapy
Nicholas Restifo, MD – National Cancer Institute

Session 102: Understanding the Tumor Microenvironment

Co-Chairs:

Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Robert W. Franz Cancer Center
Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

9:25 a.m.

Introduction
Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Robert W. Franz Cancer Center

9:30 a.m.

Genomic Approaches to the Tumor Microenvironment
Alexandra Snyder Charen, MD Merck

9:50 a.m.

Understanding the Tumor Immune Composition Using Quantitative and Spatially Resolved Imaging Mass Cytometry
Kurt A. Schalper, MD, PhD Yale School of Medicine

10:10 a.m.

Break

10:25 a.m.

Single Cell Genomics – Using a Finer Lens to Unravel Features of Human Immunity
Alexandra-Chloe Villani, PhD – Massachusetts General Hospital

10:45 a.m.

Mouse Models of the TME
Tyler Jacks, PhD – Koch Institute for Integrative Cancer Research at MIT

11:05 a.m.

Reinvigorating TILs by hyper-oxygenation
Tomasz Zal, PhD – MD Anderson Cancer Center

11:20 a.m.

Comparison of biomarker assay modalities in anti-PD-(L)1 monotherapy: a meta-analysis
Steve Lu, BS – John Hopkins University School of Medicine

11:35 a.m.

Panel Discussion

11:55 a.m.

Closing
Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

Session 103: Late-Breaking Abstract Session

Late-Breaking Abstract Session
Chair: Crystal Mackall, MD – Stanford University

Noon

Imaging of tumor infiltrating T cells with an anti-CD8 minibody 89Zr-IAB22M2C in advanced solid tumors: a phase I first-in-human study
Michael Gordon, MD – HonorHealth Research Institute

12:15 p.m.

In silico assessment of variation in TMB quantification across diagnostic platforms: Phase 1 of the Friends of Cancer Research Harmonization Project
David Fabrizio, PhD – Foundation Medicine

12:30 p.m.

Team TimIOs – A Pooled Analysis of Durable versus Transient Responders on Immunotherapy Trials
Yana Najjar, MD – University of Pittsburgh
Randy Sweis, MD – University of Chicago

12:45 p.m.

Lunch; Poster Viewing & Exhibits

Rapid Oral Abstract Presentations

Co-Chairs:
Sebastiano Battaglia, PhD – Roswell Park Comprehensive Cancer Institute
Claire Vanpouille-Box, PhD – Weill Cornell Medical College

1 p.m.

High-dimensional flow cytometry of circulating immune cells predicts clinical responses to combination Immune Checkpoint Blockade (ICB) and Radiotherapy (RT) in Gastroesophageal Cancer (GEC)
Joseph Chao, MD – City of Hope Comprehensive Cancer Center

1:05 p.m.

Fast quality gauging of tumor-infiltrating lymphocytes (TIL) for the treatment of patients with solid cancer
Georgia Paraschoudi, M.Sc. – Champalimaud Foundation

1:10 p.m.

Immunologic biomarkers in a multi-center, single arm, open label Phase II clinical trial of mFOLFOX6 and pembrolizumab in patients with advanced colorectal cancer
Matthew Farren, PhD – Emory University

1:15 p.m.

Deep learning of the immune synapse
John- William Sidhom, MSE – John Hopkins University

1:20 p.m.

Overcoming genetically-based resistance mechanisms to PD-1 blockade
Davis Torrejon, MD – UCLA Hematology-Oncology

1:25 p.m.

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang, MD, PhD –  University of Texas MD Anderson Cancer Center

1:30 p.m.

Using high dimensional mass cytometry (CyTOF) and machine assisted analysis to detect biomarkers in the immunotherapy of cancer
Carsten Krieg, PhD – Medical University of South Carolina

1:35 p.m.

Development of a next-generation sequencing-based microsatellite instability assay (MSI-NGS) for solid tumor testing
Sean Glenn, PhD – Omniseq, Inc.

1:40 p.m.

Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment
Sekwon Jang, MD – iNova/Personalis

1:45 p.m.

SIRPα blockade increases the activity of multiple myeloid lineage cells, enhances dendritic cell cross-presentation, and aids in remodeling the tumor microenvironment
Jay Hyok Chung – Aduro Biotech

1:50 p.m.

DuoBody-PD-L1x4-1BB combines checkpoint blockade and 4-1BB co-stimulation to promote antigen-specific T-cell stimulation and proliferation
Isil Altintas, PhD – Genmab

1:55 p.m.

Molecular determinants of response to PD-L1 blockade across tumor types
Romain Banchereau – Genentech

2 p.m.

CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule
Alexandre E. Michaux, PhD – Celyad SA

Concurrent Session 104: Immune Checkpoints – Beyond PD-1

Co-Chairs:

Ana Carrizosa Anderson, PhD – Harvard Medical School
Charles G. Drake, MD, PhD – Columbia University Medical Center

2:15 p.m.

Introduction
Ana Carrizosa Anderson, PhD – Harvard Medical School

2:20 p.m.

LAG-3: Signaling, Function and Potential Impact on Cancer Immunotherapy
Dario A.A. Vignali University of Pittsburgh

2:45 p.m.

Regulation of Dendritic Cell Function by TIM-3
Brian Ruffell, PhD Moffitt Cancer Center

3:10 p.m.

Break

3:25 p.m.

Targeting the TIGIT/CD226 Axis in Cancer Immunotherapy
Hassane M. Zarour, MD UPMC Hillman Cancer Center

3:50 p.m.

4-1BB and Metabolism
Ignacio Melero, MD, PhD Clinica Universidad de Navarra-FIMA

4:15 p.m.

Remodeling the tumor microenvironment – Targeting Scavenger receptors
Dhifaf Sarhan, PhD – Karolinska Institutet

4:30 p.m.

Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding
Lawrence P. Andrews, PhD – University of Pittsburgh

4:45 p.m.

Closing
Charles G. Drake, MD, PhD – Columbia University Medical Center

Concurrent Session 105: Early Phase 1 Clinical Trials

Co-Chairs:

David S. Hong, MD – University of Texas MD Anderson Cancer Center
Patricia LoRusso, DO – Yale University

2:15 p.m.

Introduction
David S. Hong, MD – University of Texas MD Anderson Cancer Center

2:20 p.m.

Phase 1 study using mogamulizumab (KW-0761) to deplete regulatory T cells in combination with checkpoint inhibitors durvalumab (MEDI4736) or tremelimumab in subjects with advanced solid tumors
Dmitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

2:35 p.m.

First-in-human phase 1 dose-escalation trial of the potent and selective next generation transforming growth factor-β receptor type 1 (TGF-βR1) inhibitor LY3200882 in patients with advanced cancers
Timothy Yap, MD – University of Texas MD Anderson Cancer Center

2:50 p.m.

Expert Discussant
Zihai Li, MD, PhD – MUSC Hollings Cancer Center

3:00 p.m.

The GAPVAC approach of actively personalized peptide vaccination for patients with newly diagnosed glioblastoma
Hideho Okada, MD, PhD – University of California, San Francisco, USA and Parker Institute for Cancer Immunotherapy

3:15 p.m.

The Personal Vaccine, NEO-PV-01 with anti-PD1, Induces Neoantigen-Specific De Novo Tumor-Related Immunity in Patients with Advanced Cancer
Siwen Hu-Lieskovan, MD, PhD – Ronald Reagan UCLA Medical Center

3:30 p.m.

Expert Discussant
Drew Pardoll, MD, PhD – Johns Hopkins University

3:40 p.m.

A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma
Diwakar Davar, MD – University of Pittsburgh Department of Medicine

3:55 p.m.

Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
Adnam Khattak, MD – Perth University

4:10 p.m.

The anti–LAG-3 antibody MK-4280 as monotherapy and in combination with pembrolizumab for advanced solid tumors: first-in-human phase 1 dose-finding study
Nehal Lakhani, MD, PhD – START-Midwest

4:25 p.m.

Phase 1 dose-finding study of the anti–TIGIT antibody MK-7684 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
Talia Golan – Sheba Medical Center

4:40 p.m.

Expert Discussant
Aung Naing, MD, FACP – University of Texas MD Anderson Cancer Center

4:50 p.m.

Break

Concurrent Session 106: Cytokines Reinvented

Co-Chairs:

James L. Gulley, MD, PhD, FACP – National Cancer Institute
Darrell J. Irvine, PhD – Massachusetts Institute of Technology

5:05 p.m.

Introduction
James L. Gulley, MD, PhD, FACP – National Cancer Institute

5:07 p.m.

NHS/IL15
Marijo Bilusic, MD, PhD National Cancer Institute, National Institutes of Health

5:27 p.m.

Harnessing Potent Immune Agonist Pathways through Kinetic Engineering
Deborah Charych, PhD

5:47 p.m.

Locoregional Cytokine Immunotherapy
K. Dane Wittrup, PhD Massachusetts Institute of Technology

6:07 p.m.

Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma
Adi Diab, MD – The University of Texas MD Anderson Cancer Center

6:17 p.m.

Decoy-resistant Interleukin-18 overcomes the soluble immune checkpoint IL-18BP to unlock a potent immunotherapeutic cytokine pathway
Aaron Ring – Yale School of Medicine

6:27 p.m.

Closing
Darrell J. Irvine, PhD – Massachusetts Institute of Technology

Concurrent Session 107: Metabolic Manipulation of the TME

Co-Chairs:

Greg M. Delgoffe, PhD – University of Pittsburgh
Michele W. Teng, PhD – QIMR Berghofer Medical Research Institute

5:05 p.m.

Targeting the Adenosinergic Pathway to Improve Combination Immunotherapy
Michele W. Teng, PhD – QIMR Berghofer Medical Research Institute

5:25 p.m.

Enhancement of Oncolytic Virus Immunotherapy Through Vector-Encoded Metabolic Modulation of the Tumor Microenvironment
Greg M. Delgoffe, PhD – University of Pittsburgh

5:45 p.m.

Chronic endoplasmic reticulum stress drives mitochondrial exhaustion of CD8 TILs
Jessica Thaxton, PhD MSCR – Medical University of South Carolina

6:00 p.m.

Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity
Esra Akbay, PhD – University of Texas Southwestern Medical

6:15 p.m.

Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma
Ashley Menk, BS – University of Pittsburgh

6:30 p.m.

Poster Reception

Saturday, Nov. 10

Annual Meeting

7:20 a.m.

Annual Meeting Organizer Welcome
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital

Session 200: Policy Committee Update Session

7:25 a.m.

Policy Committee Update
Samir N. Khleif, MD Georgetown University

Session 201: Smalley Keynote

7:40 a.m.

Introduction
Lisa Butterfield, PhD – University of Pittsburgh

7:45 a.m.

Engineering T cells to Effectively Target Tumors and Overcome Obstacles To Achieving Tumor Eradication
Philip D. Greenberg, MD – Fred Hutchinson Cancer Research Center

Session 202: Cell-Based Therapies for Solid Tumors

Co-Chairs:

Chantale Bernatchez, PhD – University of Texas MD Anderson Cancer Center 
Mitchell Cairo, MD – New York Medical College at Maria Fareri Children's Hospital   
Crystal L. Mackall, MD – Stanford University

8:30 a.m.

Introduction
Crystal Mackall, MD – Stanford University

8:35 a.m.

Pre-Clinical Approaches to CAR NK cell Therapy in Neuroblastoma and Sarcomas
Mitchell Cairo, MD – New York Medical College at Maria Fareri Children's Hospital   

8:55 a.m.

CAR T cell Therapies in Glioblastoma
Christine Brown, PhD – City of Hope National Medical Center

9:15 a.m.

Break

9:30 a.m.

CAR T Cell Therapies in Solid Tumors
Gianpietro Dotti, MD – University of North Carolina, Chapel Hill

9:50 a.m.

TIL Therapy for Melanoma and Beyond - Lessons Learned on Optimal Tumor Rejection Antigens for Solid Tumors
Steven A. Rosenberg, MD, PhD – National Cancer Institute, National Institutes of Health

10:10 a.m.

Tscm-like CD8+ T-cells are Associated with Adoptive TIL Therapy Response and Survival
Matthew Beatty, PhD – Moffitt Cancer Center

10:25 a.m.

Next-generation retroviral vector with membrane-anchored IL-12 to improve adoptive T cell immunotherapy and enhance its safety
Ling Zhang, PhD – National Institutes of Health

10:40 a.m.

Panel Discussion

11:00 a.m.

Closing
Chantale Bernatchez, PhD – University of Texas MD Anderson Cancer Center


Organized in collaboration with the International Society for Cellular Therapy (ISCT).

Concurrent Session 203: National Cancer Institute Update Session

11:05 a.m.

National Cancer Institute Update: Immuno-oncology Research at the National Cancer Institute
Norman E. Sharpless, MD – National Cancer Institute

Concurrent Session 204: Clinical Management of Cell Therapy Administration

Co-Chairs:

Harriet Kluger, MD – Yale University
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital  

11:05 a.m.

Introduction
Harriet Kluger, MD – Yale University

11:10 a.m. Tumor Infiltrating Lymphocytes
Ronnie Shapira, MD -Frommer, MD – Ella Institute for Immuno-Oncology

11:30 a.m.

Clinical and Biomarker Correlates and Management of Common Cellular Therapy Toxicities Including Cytokine Release Syndrome and Neurotoxicity
Eric L. Smith, MD, PhD – Memorial Sloan Kettering Cancer Center


11:50 a.m. CAR T Cell Therapy and Cell Therapy in Pediatric Cancer Treatment
Shannon L. Maude, MD, PhD – Children's Hospital of Philadelphia Center for Childhood Cancer Research

12:10 p.m. Q&A

12:25 p.m. Closing
Krista Rubin, MS, FNP-BC – Massachusetts General Hospital

Session 205: Late-Breaking Abstract Session

Chair: Naiyer A. Rizvi, MD – Columbia University Medical Center

11:35 a.m.

Pembrolizumab in combination with chemoradiotherapy (CRT) in human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)
Steven F. Powell, MD – Sanford Cancer Center

11:50 a.m.

Expert Discussant
Charles Drake, MD, PhD – Columbia University Medical Center

Concurrent Session 206: SITC Sparkathon Update

12:05 p.m.

Team METIOR Incubator: Strengthening Communication Across Scientific Disciplines
Alexandra Cadena, BS/BA – MD Anderson Cancer Center
Sebastiano Battaglia – Roswell Park Cancer Institute

Session 207: Presidential Session

1:55 p.m.

Introduction
Lisa H. Butterfield, PhD – University of Pittsburgh

2 p.m.

PAK4 inhibition reverses immune cell exclusion and overcomes resistance to checkpoint blockade therapy
Gabriel Abril-Rodriguez, MS – University of California, Los Angeles

2:15 p.m.

Adaptive plasticity of IL10+ and IL35+ regulatory T cells and their cooperative regulation of anti-tumor immunity
Hiroshi Yano, BS – University of Pittsburgh

2:30 p.m.

Expert Discussant
Nicholas P. Restifo, MD – National Cancer Institute

2:40 p.m.

Endoplasmic reticulum stress-induced transcription factor C/EBP homologous protein (Chop) thwarts effector T cell activity in tumors through repression of T-bet
Yu Cao, PhD – H. Lee Moffitt Cancer Center & Research Institute

2:55 p.m.

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors
Kristin Anderson, PhD – Fred Hutchinson Cancer Research Center

3:10 p.m.

Expert Discussant
Stanley R. Riddell, MD – Fred Hutchinson Cancer Research Center

Rapid Oral Abstract Presentations

Chair:
Julie Decock, PhD – Qatar Biomedical Research Institute

12:35 p.m.

Pharmacodynamic Activity of MEDI1873, a Glucocorticoid-Induced Tumor Necrosis Factor Family-Related protein (GITR) Agonist Molecule, Administered Intravenously to Patients with Advanced Solid Tumors
Nicholas Durham, PhD – MedImmune

12:40 p.m.

Intratumoral injection of a novel oncolytic virus, Voyager V1 (VV1): completed phase 1 monotherapy in patients with refractory solid tumors
Steven Powell, MD – Sanford Cancer Center

12:45 pm.

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors
Kohei Shitara, MD – National Cancer Hospital East

12:50 p.m.

Initial results from a phase 1a/b study of etigilimab (OMP-313M32), an anti-T cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody, in advanced solid tumors
Sunil Sharma, MD – Honor Health Research Institute

12:55 p.m.

A phase 1 study of ALX148: CD47 blockade in combination with anticancer antibodies to bridge innate and adaptive immune responses for advanced malignancy
Nehal Lakhani, MD, PhD – START Midwest

1 p.m.

Phase I dose-finding study of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced solid tumors or lymphomas
Funda Meric-Bernstam, MD – MD Anderson Cancer Center

1:05 p.m.

Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial
Luc R. Desnoyers, PhD – CytomX Therapeutics, Inc.

1:10 p.m.

Preliminary Biomarker Analysis of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor
Kai He, MD, PhD

1:15 p.m.

A phase 1b/2 trial of lenvatinib in combination with pembrolizumab in patients with non-small cell lung cancer
Marcia Brose – Abramson Cancer Center of the University

1:20 p.m.

HyPeR: A Phase 1, Dose Escalation Study of Guadecitabine (SGI-110) a Second Generation HypoMethylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours
Malaka Ameratunga, MBBS – Royal Marsden Hospital

1:25 p.m.

Interleukin-6 gene expression is highly upregulated in immune checkpoint mediated enterocolitis
Daniel Johnson, MD – MD Anderson Cancer Center

1:30 p.m.

Clinical efficacy of immune checkpoint inhibitors in patients with small cell lung cancer is associated with high tumor mutational burden and development of immune-related adverse events
Biagio Ricciuti, MD – Dana-Farber Cancer Institute

12:20 p.m.

Lunch; Poster Viewing & Exhibiting

3:20 p.m.

Break

Concurrent Session 208: Advances in Immunotherapy of Breast and Gynecologic Cancers

Co-Chairs:

George Plitas, MD – Memorial Sloan Kettering Cancer Center
Alessandro Santin, MD – Yale School of Medicine

3:35 p.m.

Introduction
George Plitas, MD – Memorial Sloan Kettering Cancer Center     

3:40 p.m.

Advances in Immunotherapy of Gynecologic Malignancies
Dmitrity Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center


4:05 p.m. Breast Cancer
Sylvia Adams, MD – New York University Cancer Institute

4:30 p.m.

Increased tumor-resident memory T cells in breast cancer is associated with improved prognosis
Paul Neeson, PhD – Peter MacCallum Cancer Centre

4:45 p.m.

Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma
David Page, MD – Providence Portland Medical Center

Concurrent Session 209: Advances in Immunotherapy of GI and Pancreatic Cancer

Co-Chairs:

Dung T. Le, MD – The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Herbert J. Zeh, MD – University of Pittsburgh Medical Center

3:35 p.m.

Introduction
Dung T. Le, MD – The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

3:40 p.m. Augmenting T cell Immunity in Pancreatic Cancer
Stephanie K. Dougan, PhD – Dana-Farber Cancer Institute

3:55 p.m.

Reprograming the Pancreatic Tumor Microenvironment to Improve Responses to Therapy
David G. DeNardo, PhD – Washington University


4:10 p.m.

Exploiting the Complex Stromal Biology of Pancreas Cancer
Sunil R. Hingorani, MD, PhD – Fred Hutchinson Cancer Research Center


4:25 p.m. Immunotherapy in Hepatocellular Carincoma (HCC)
Kevin Staveley-O'Carroll, MD, PhD, MBA – University of Missouri

4:40 p.m.

Lipid accumulation in the pancreatic tumor microenvironment drives metabolic exhaustion of CD8+ T cells
Teresa Manzo, PhD – European Institute of Oncology, Milan

4:55 p.m. Closing
Herbert J. Zeh, MD – UT Southwestern Medical Center 

Concurrent Session 210: Advances in Immunotherapy of GU Tumors

Co-Chairs:

Arjun V. Balar, MD – Perlmutter Cancer Center - New York University Langone Medical Center
Padmanee Sharma, MD, PhD – University of Texas MD Anderson Cancer Center 

3:35 p.m. Introduction
Arjun V. Balar, MD – Perlmutter Cancer Center – New York University Langone Medical Center

3:40 p.m.

The Management of Urothelial Bladder Cancer in the Era of Cancer Immunotherapy
Arjun V. Balar, MD – Perlmutter Cancer Center - New York University Langone Medical Center


4:00 p.m.

Clinical Genomics and Cancer Immunotherapy
Eliezer Van Allen, MD – Dana-Farber Cancer Institute


4:20 p.m.

From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy
Padmanee Sharma, MD, PhD – University of Texas MD Anderson Cancer Center

4:40 p.m.

Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and prolonged survival following treatment with the A2AR antagonist, CPI-444
Lawrence Fong, MD – University of California

4:55 p.m. Closing
Padmanee Sharma, MD, PhD – University of Texas MD Anderson Cancer Center 

Concurrent Session 211: Advances in Immunotherapy of Hematologic Malignancies

Co-Chairs:

Joshua Brody, MD – Mount Sinai School of Medicine
Elizabeth Shpall, MD – University of Texas MD Anderson Cancer Center

3:35 p.m.

Off-The-Shelf Engineered NK Cells for The Treatment of Cancer
Katayoun Rezvani, MD, PhD – University of Texas MD Anderson Cancer Center

4:00 p.m. CAR T cells
Stanley R. Riddell, MD – Fred Hutchinson Cancer Research Center

4:25 p.m. Checkpoint Blockade
Thomas Marron, PhD – Mount Sinai Hospital

4:45 p.m.

LSD1 Inhibition Promotes CD141Hi Dendritic Cell Differentiation in Myelodysplastic Syndromes
Pragya Srivastava, PhD – Roswell Park Comprehensive Cancer Center

Organized in collaboration with the American Society of Blood and Marrow Transplant (ASBMT).

Concurrent Session 212: Advances in Immunotherapy of Lung, Head and Neck Cancer

Co-Chairs:

Naiyer A. Rizvi, MD – Columbia University Medical Center
Tanguy Seiwert, MD – University of Chicago

3:35 – 3:40 p.m.

Introduction
Naiyer A. Rizvi, MD – Columbia University Medical Center

3:40 – 4:05 p.m.

The Influence of the Cancer Genome on Efficacy of Immunotherapy in Lung Cance
Nadeem Riaz, MD, MSc – Memorial Sloan Kettering Cancer Center


4:05  4:30 p.m. Head and Neck Cancer
Tanguy Seiwert, MD – University of Chicago

4:30 - 4:45 p.m.

Identification and profiling of neoantigen-specific T cells in NSCL cancer patients treated with atezolizumab
Alessandra Nardin, DVM – immunoSCAPE

4:45 – 5 p.m.

Peripheral T cell dynamics in resectable NSCLC patients treated with neoadjuvant PD-1 blockade
Jiajia Zhang, MD – MPH – Johns Hopkins University

Concurrent Session 213: Advances in Immunotherapy of Pediatric Malignancies

Co-Chairs:

Kavita M. Dhodapkar, MD – Emory University
Crystal L. Mackall, MD – Stanford University

3:35 p.m.

Introduction
Kavita Dhodapkar, MD – Emory University

3:40 p.m.

Preventing Relapse After CAR T cell Immunotherapy for B cell Malignanices
Terry J. Fry, MD – Children's Hospital of Colorado

4:00 p.m.

Vaccines Targeting Malignant Brain Tumors
Duane A. Mitchell, MD, PhD – University of Florida


4:20 p.m. Tumor Microenvironment
Kavita M. Dhodapkar, MD – Emory University

4:40 p.m.

Characterization of Anti-Tumor Immune Responses and Effects on Survival of Neoadjuvant Oncolytic Virotherapy in Spontaneous Osteosarcoma
Kelly Makielski, DVM, MS – University of Minnesota

4:55 p.m. Closing

Crystal Mackall, MD – Stanford University

5 p.m.

Break

Concurrent Session 214: Basic Biology of Tregs

Co-Chairs:

Sergio A. Quezada, PhD – University College London
Dario A.A. Vignali, PhD – University of Pittsburgh

5:10 p.m.

Targeting Regulatory T Cells for Therapeutic Gain: Means and Mechanisms
Sergio A. Quezada, PhD – University College London


5:31 p.m.

The TNFR2 Treg Receptor and Oncogene: Dominant Antagonistic Antibody Targeting for Cancer
Denise L. Faustman, MD, PhD – Harvard Medical School


5:51 p.m.

Lactic acid metabolically supports the high suppressive function of tumor infiltrating regulatory T cells
McLane Watson, BS – University of Pittsburgh

6:01 p.m.

Anti-CTLA4 activation of intratumoral NK cells may contribute to intratumoral Treg depletion
Erica Stone, PhD – Wistar Institute

6:11 p.m.

Neuropilin-1 Stabilizes Human Tregs in Cancer Patients Leading to More Potent Suppressive Function
Christopher A. Chuckran, BS – University of Pittsburgh School of Medicine

6:21 p.m.

Q&A

Concurrent Session 215: Myeloid Derived Suppressive Populations

Co-Chairs:

Dmitry I. Gabrilovich, MD, PhD – The Wistar Institute
Sourav Ghosh, PhD – Yale School of Medicine

5:10 p.m.

Innate Immune Checkpoints and Cancer Immunotherapy
Sourav Ghosh, PhD – Yale School of Medicine

5:35 p.m.

Regulation of Myeloid-Derived Suppressor Cells in Cancer
Dmitry I. Gabrilovich, MD, PhD – The Wistar Institute

6:00 p.m.

Reprogramming suppressive myeloid cells in tumor microenvironment with pepinemab, first-in-class Semaphorin 4D Mab, enhances combination immunotherapy
Greg Lesinski, PhD, MPH – Winship Cancer Institute of Emory University

6:15 p.m.

Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostate hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populations
George A. Dominguez, PhD – Anixa Biosciences

Concurrent Session 216: Role of B cells in Immunotherapy & Toxicity

Co-Chairs:

Tullia C. Bruno, PhD – University of Pittsburgh
Madhav Dhodapkar, MD – Emory University

5:10 p.m.

Introduction
Madhav Dhodapkar, MD – Emory University

5:15 p.m.

Role of B cells in Tumors
Tullia C. Bruno, PhD – University of Pittsburgh

5:35 p.m.

Role of B cells in Autoimmunity
Kavita M. Dhodapkar, MD – Emory University

5:55 p.m.

B-cells and tertiary lymphoid structures (TLS) predict response to immune checkpoint blockade (ICB)
Sangeetha Reddy, MD, MSci – MD Anderson Cancer Center

6:10 p.m.

Anti-Tumor Immune Responses in Metastatic Breast Cancer Exceptional Responder Patients
William H. Robinson, MD, PhD – Stanford University School of Medicine

6:25 p.m.

Closing
Tullia C. Bruno, PhD – University of Pittsburgh 

Award Ceremony

6:35 p.m.

Award Ceremony

Poster Reception

7 p.m.

Poster Reception

Sunday, Nov. 11

Annual Meeting

7:30 a.m.

Annual Meeting Organizer Welcome
Dario A.A. Vignali, PhD – University of Pittsburgh

7:35 a.m.

Cancer Immunotherapy Trials Network Update 

Martin A. Cheever, MD – Fred Hutchinson Cancer Research Center

Concurrent Session 301: Next Generation Bispecifics and Antibody-Like Molecules

Co-Chairs:

Ignacio Melero, MD, PhD – FIMA - University of Navarra
Farhad Ravandi, MD – University of Texas MD Anderson Cancer Center

8:05 a.m.

Introduction
Ignacio Melero, MD, PhD – FIMA-University of Navarra

8:10 a.m.

Next Generation T Cell Bispecific Antibodies and Fusion Proteins for Cancer Immunotherapy
Pablo Umaña, PhD – Roche Glycart AG

8:35 a.m.

Blinatumomab: Can We Improve Efficacy Using Checkpoint Inhibitors
Dirk Nagorsen, MD, PhD – Amgen Inc.

9 a.m.

Chimeric Antibodies in AML: Hope or Reality?
Farhad Ravandi, MD – University of Texas MD Anderson Cancer Center

9:25 a.m.

A new immunomodulatory strategy of inhibiting the glyco-immune checkpoint axis with EAGLE technology to treat cancer
Li Peng, PhD – Palleon Pharmaceuticals

9:40 a.m.

FS120 mAb2, a dual agonist bispecific antibody targeting OX40 and CD137, activates T cells in vitro and induces potent, FcγR-independent anti-tumour activity
Miguel Gaspar, PhD – F-star Biotechnology ltd

9:55 a.m.

Immuno-oncology tHERApy with HERA-GITRL: the novel hexavalent human GITR agonist activates T cells and promotes anti-tumor efficacy independent of Fc-functionality
David M. Richards – Apogenix AG

10:10 a.m.

Closing
Farhad Ravandi, MD – University of Texas MD Anderson Cancer Center

10:15 a.m.

Break

Concurrent Session 302: Clinical Trials Session

Co-Chairs:
Michael Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
Mario Sznol, MD – Yale Cancer Center

8:10 a.m. Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors
Amod Sarnaik, MD – H. Lee Moffitt Cancer Center & Research

8:25 a.m.

Infusion of TGFβ-resistant EBV-specific T-cells post cytoreductive chemotherapy is safe and associated with clinical benefit in patients with recurrent/metastatic NPC
Christopher DeRenzo, MD – St. Jude Children’s Research Hospital

8:40 a.m. Expert Discussant

Cara Haymaker, PhD – University of Texas MD Anderson Cancer Center


8:50 a.m. Using high dimensional mass cytometry (CyTOF) and machine assisted analysis to detect biomarkers in the immunotherapy of cancer
Carsten Krieg, PhD – Medical University of South Carolina

9:05 a.m. Monalizumab in combination with cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): clinical and translational biomarker results
Roger Cohen – University of Pennsylvania

9:20 a.m. Combination of subcutaneous selicrelumab (CD40 agonist) and vanucizumab (anti-Ang2/VEGF) in patients with solid tumors demonstrates early clinical activity and a favorable safety profile
Emiliano Calvo, MD, PhD – START Madrid

9:35 a.m. A phase 1, open-label, dose-escalation study of enoblituzumab in combination with pembrolizumab in patients with select solid tumors
Charu Aggarwal, MD, MPH – University of Pennsylvania

9:50 a.m. Phase 2 trial of mocetinostat in combination with durvalumab in NSCLC patients with progression on prior checkpoint inhibitor therapy
Manish Patel, DO – University of Minnesota Medical Center

10:05 a.m. Expert Discussant
Elad Sharon, MD, MPH – National Institutes of Health

Concurrent Session 303: Immunoscore Update Session

10:30 a.m.

Immunoscore Update 
Jerome Galon, PhD – Universite Pierre Et Marie Curie, Sorbonne Universites

Concurrent Session 304: Hot Topic Symposium: Lessons from Recent Immuno-Oncology Trials When Active

10:45 a.m.

Introduction
Marc Theoret, MD – U.S. Food & Drug Administration

10:50 a.m.

Strength of Rationale, Potential Pharmacodynamic/Pharmacokinetic Considerations
Jason J. Luke, MD, FACP – University of Chicago

11:20 a.m.

Dosing and Dosage Regimen
Renzo Canetta, MD

11:35 a.m.

Biomarker Selection Considerations
Roy S. Herbst, MD, PhD – Yale Cancer Center

11:05 a.m.

Clinical Development Strategy/Trial Design
Mario Sznol, MD – Yale Cancer Center

11:50 a.m.

Panel Discussion
Moderators: 
Marc Theoret, MD – U.S. Food & Drug Administration
Helen Chen, MD – National Cancer Institute
Panelists:
Renzo Canetta, MD
Roy S. Herbst, MD, PhD – Yale Cancer Center
Jason J. Luke, MD, FACP – University of Chicago
Rajeshwari Sridhara, PhD – U.S. Food & Drug Administration
Mario Sznol, MD – Yale Cancer Center

Adjourn

12:15 p.m.

Thank you for attending SITC 2018!

2287.jpg



2263.jpg

1850.jpg

1683.jpg

2571.jpg